Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SELECT - Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity

Trial Profile

SELECT - Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Cardiovascular disorders; Myocardial infarction; Obesity; Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms SELECT
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 08 Mar 2024 According to a Novo Nordisk media release, Dr. A. Michael Lincoff, Professor of Medicine at Cleveland Clinic and the lead study author of the SELECT outcomes trial.
    • 08 Mar 2024 According to a Novo Nordisk media release, Novo Nordisk has also filed for a label expansion in the EU, and a decision is expected in 2024.
    • 08 Mar 2024 According to a Novo Nordisk media release, company announced that the US Food and Drug Administration (FDA) has approved a label expansion for Wegovy based on a supplemental New Drug Application (sNDA) for the indication of reducing risks of major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal heart attack (myocardial infarction) or non-fatal stroke in adults with either overweight or obesity and established cardiovascular disease (CVD).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top